Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 +1.28%83 FCF Margin % is 34.59% as of Mar. 2026, which is 49% above its 10-year median of 23.26. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 961 Drug Manufacturers companies, TTY Biopharm Co ranks better than 94.9% on this metric.
The historical rank and industry rank for TTY Biopharm Co's FCF Margin % or its related term are showing as below:
ROCO:4105'
s FCF Margin % Range Over the Past 10 Years
Min: 8.16 Med: 23.26 Max: 29.85
Current: 27.34
During the past 13 years, the highest FCF Margin % of TTY Biopharm Co was 29.85%. The lowest was 8.16%. And the median was 23.26%.
ROCO:4105's FCF Margin % is ranked better than 94.9% of 961
companies
in the Drug Manufacturers industry
Industry Median: 2.59
vs ROCO:4105: 27.34
TTY Biopharm Co FCF Margin % Related Terms
TTY Biopharm Co FCF Margin % Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTY Biopharm Co (ROCO:4105) has a FCF Margin % of 34.59% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TTY Biopharm Co and its competitors. This is 49% above median its historical median of 23.26. Over the past decade, TTY Biopharm Co's FCF Margin % has ranged from 8.16 to 29.85. According to the industry distribution chart, TTY Biopharm Co ranks #49 out of 961 companies in the Drug Manufacturers industry, placing it in the top 5.1%.
Is TTY Biopharm Co's FCF Margin % too high?
TTY Biopharm Co's current FCF Margin % of 34.59% is 49% above median its 10-year median of 23.26. Over the past 10 years, this metric has ranged from a low of 8.16 to a high of 29.85. The Drug Manufacturers industry median FCF Margin % is 2.59. TTY Biopharm Co's value of 34.59% is 1235.5% above this industry median. Based on the distribution chart, TTY Biopharm Co ranks #49 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #49 out of 961 companies for FCF Margin %. This places TTY Biopharm Co in the top 5% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.59. TTY Biopharm Co's value of 34.59% is 1235.5% above this benchmark. Historically, TTY Biopharm Co's own FCF Margin % has ranged from 8.16 to 29.85 over the past decade. While the company's 10-year median is 23.26 vs. the industry median of 2.59, TTY Biopharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.59, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current FCF Margin % of 34.59% is 1235.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current FCF Margin % is 34.59%, which is 49% above median its own 10-year median of 23.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.56, compared to a current price of NT$79.10 — trading 9.7% below its estimated fair value. The current FCF Margin % is 34.59%, which is 49% above median its 10-year median of 23.26 and 1235.5% above the Drug Manufacturers industry median of 2.59. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current FCF Margin % is 34.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$79.10 is trading 9.7% below its estimated GF Value™ of NT$87.56.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
FCF Margin %: 34.59% (49% above median its 10-year median of 23.26)
GF Value™: NT$87.56 vs. price of NT$79.10 (9.7% below fair value)
Industry Position: 1235.5% above the Drug Manufacturers median (#49 of 961)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score
Get the complete analysis for ROCO:4105
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
